Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Icon ( (ICLR) ) is now available.
On August 26, 2025, ICON plc released its unaudited interim financial statements for the period from January 1, 2025, to August 7, 2025. The release of these financial statements provides stakeholders with insights into the company’s financial performance and operational efficiency during this period, which is crucial for assessing its market positioning and strategic direction.
The most recent analyst rating on (ICLR) stock is a Hold with a $200.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score is driven by strong financial performance and positive technical indicators. The company’s robust profitability and efficient cash flow management are significant strengths. While the earnings call provided positive guidance, concerns about revenue declines and market volatility slightly offset these strengths. The stock’s valuation is fair, but the lack of a dividend yield may deter some investors.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a company operating in the clinical research industry, providing outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company focuses on delivering clinical development solutions that enhance the efficiency and effectiveness of clinical trials.
Average Trading Volume: 1,332,616
Technical Sentiment Signal: Sell
Current Market Cap: $13.36B
See more insights into ICLR stock on TipRanks’ Stock Analysis page.